Decreased levels of KLF9 have been implicated in a hyperproliferative B‐cell response and defective Ig production (Good & Tangye, 2007; Savignac et al., 2010) and a predictive marker of sensitivity to bortezomib treatment in MM (Mannava et al., 2012; Ri, 2016). The gene discussed is KLF9; the disease is Miyoshi myopathy.